AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Cash Deal

NORTH CHICAGO, Ill. — AbbVie Inc. officially announced on Monday, June 22, 2026, that it has entered into a definitive agreement to acquire Apogee Therapeutics, a California-based biotechnology company, in an all-cash transaction valued at approximately $10.9 billion. The acquisition, which has been unanimously approved by the boards of directors of both companies, marks AbbVie’s largest bolt-on purchase since its 2019 acquisition of Allergan.

Under the terms of the agreement, AbbVie will pay $135.11 per share for all outstanding shares of Apogee Therapeutics, representing a significant premium over the biotech firm's recent market valuation. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including regulatory approvals and the approval of Apogee’s shareholders.

Strengthening an Immunology Powerhouse

The acquisition is strategically designed to expand AbbVie’s robust pipeline in inflammatory and immunological diseases. Apogee Therapeutics brings a suite of differentiated clinical-stage assets to the table, most notably zumilokibart (APG777), a subcutaneous, long-acting monoclonal antibody targeting IL-13.

Zumilokibart is currently being developed for atopic dermatitis, with Phase 2 clinical data showing significant skin clearance and potential for maintenance regimens as infrequent as twice yearly. This long-acting profile could provide a competitive alternative to existing biologics, fitting squarely into AbbVie’s immunology franchise, which includes blockbuster treatments like Skyrizi and Rinvoq.

Strategic Rationale and Market Impact

AbbVie, which has been seeking new growth drivers to maintain its lead in the autoimmune market following the patent expiration of Humira, views the acquisition as a long-term value creator. By acquiring Apogee, AbbVie secures a pipeline of assets that address high-need conditions such as asthma and chronic obstructive pulmonary disease (COPD), alongside atopic dermatitis.

"The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders," said Robert A. Michael, chairman and chief executive officer of AbbVie.

Quote Section

According to officials, the acquisition of Apogee Therapeutics represents a strategic move to bolster AbbVie’s immunology portfolio, further solidifying its dominant position in the healthcare market and enhancing its capabilities in treating chronic autoimmune diseases.

Why It Matters

This deal underscores a prevailing trend in the biopharmaceutical industry: large firms are increasingly willing to pay significant premiums for clinical-stage assets to de-risk their future revenue pipelines. For patients, the development of zumilokibart could eventually offer a more convenient treatment schedule for chronic inflammatory conditions, potentially reducing the frequency of required injections. For investors, the purchase price reflects AbbVie’s confidence in the future peak sales potential of Apogee's pipeline.

Key Facts at a Glance

• Deal Value: Approximately $10.9 billion in cash.

• Acquisition Price: $135.11 per share of Apogee Therapeutics.

• Key Asset: Zumilokibart (APG777), a long-acting IL-13 monoclonal antibody.

• Targeted Conditions: Atopic dermatitis, asthma, and other type-2 inflammatory diseases.

• Expected Closing: Third quarter of 2026.

FAQ

1. Why is AbbVie acquiring Apogee Therapeutics? AbbVie is looking to strengthen its immunology franchise by acquiring Apogee’s clinical-stage pipeline, specifically its long-acting treatments for inflammatory diseases like atopic dermatitis.

2. What is zumilokibart? Zumilokibart is a long-acting monoclonal antibody designed to target IL-13, a cytokine that drives inflammation in conditions such as eczema, with the potential for infrequent dosing.

3. What happens to Apogee’s ongoing clinical trials? The development of Apogee’s pipeline assets, including Phase 3 trials for zumilokibart, is expected to continue under AbbVie's ownership once the transaction closes in Q3 2026.

Source: AbbVie Corporate, Apogee Therapeutics, FirstWord Pharma